Efficacy and Safety of Canagliflozin (TA-7284) in Patients With Diabetic Nephropathy

PHASE3CompletedINTERVENTIONAL
Enrollment

308

Participants

Timeline

Start Date

February 15, 2018

Primary Completion Date

January 21, 2021

Study Completion Date

January 21, 2021

Conditions
Diabetic Nephropathy
Interventions
DRUG

Canagliflozin

Canagliflozin 100mg orally once daily

DRUG

Placebo

Placebo orally once daily

Trial Locations (26)

Unknown

Research site, Aichi

Research site, Chiba

Research site, Fukuoka

Research site, Fukushima

Research site, Gunma

Research site, Hiroshima

Research site, Hokkaido

Research site, Hyōgo

Research site, Ibaraki

Research site, Kagawa

Research site, Kagoshima

Research site, Kanagawa

Research site, Kumamoto

Research site, Mie

Research site, Nagano

Research site, Nagasaki

Research site, Okinawa

Research site, Osaka

Research site, Ōita

Research site, Saitama

Research site, Shizuoka

Research site, Tochigi

Research site, Tokyo

Research site, Wakayama

Research site, Yamagata

Research site, Yamaguchi

All Listed Sponsors
lead

Mitsubishi Tanabe Pharma Corporation

INDUSTRY